Morgan Stanley raised the firm’s price target on Halozyme (HALO) to $94 from $78 and keeps an Overweight rating on the shares after the company reported “strong” Q4 results. The firm believes 2026 will be “another strong year,” driven by royalty revenues, expanding ENHANZE partnerships and progressing Hypercon and Surf Bio tech after the acquisitions, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme price target raised to $90 from $75 at Benchmark
- Halozyme price target raised to $75 from $65 at Wells Fargo
- Halozyme Earnings Call Highlights Royalty-Fueled Growth
- Halozyme: Strong Royalty Momentum and Underappreciated Multi‑Year Earnings Power Support Buy Rating
- Halozyme reaffirms FY26 non-GAAP EPS view $7.75-$8.25, consensus $8.18